Life Sciences

  • April 09, 2026

    Merck Beats 295 Zostavax Suits Over Missed Deadlines

    A Pennsylvania federal judge has tossed 295 cases against Merck & Co. Inc. in the multidistrict litigation alleging its Zostavax shingles vaccine caused the disease, with the court reasoning that the plaintiffs' inactivity doomed the cases.

  • April 09, 2026

    McKinsey Settles Liability For $125M In Purdue Ch. 11

    Consulting firm McKinsey & Co. has agreed to pay $125 million to former client Purdue Pharma LP to settle potential claims related to its work advising Purdue on the sale and marketing of opioids, tying up another loose end in the nearly seven-year-old Chapter 11 case.

  • April 09, 2026

    Nonprofit Insurer Wants To Seek AstraZeneca Claims Revival

    EmblemHealth asked a Massachusetts federal judge to let it seek First Circuit intervention against a decision that cut in half its proposed class action accusing AstraZeneca unit Alexion of using sham patents to protect blood disorder treatment Soliris from biosimilar rivals.

  • April 09, 2026

    Philly Injection Site Row Judge Rejects Nonprofit's 'Ploy'

    A Pennsylvania federal judge on Thursday called the addition of overdose prevention nonprofit Safehouse's president as a counterclaim plaintiff in the government's suit to stop it from launching a safe-injection site in Philadelphia a "ploy" to add another to the ranks of those claiming the government infringed  the group's religious freedom.

  • April 09, 2026

    Abiomed Can't Escape Blood Pump Patent Case

    A Massachusetts federal judge has refused to let a Johnson & Johnson MedTech subsidiary dodge claims that it infringed a blood pump patent, the latest event in a wider legal battle launched against it by a unit of Swedish medical device company Getinge AB.

  • April 09, 2026

    Ecolab Says Personal Injury Law Firm Holding Back $148K

    Ecolab and its self-funded employee benefit plan have accused a North Carolina personal injury firm of withholding around $148,000 in settlement funds the food safety company says it's owed for covering a worker's medical bills after a car accident.

  • April 09, 2026

    Ex-Pharmacy Director Denies Using Trade Secrets At New Job

    A former director at a specialty infusion therapy pharmacy urged a New Jersey federal court to reject her former employer's bid to block her from working for a rival, arguing that her new job does not pose any threat of imminent harm to her former company.

  • April 09, 2026

    US Again Urges High Court To Back Drug Price Program

    The administration of President Donald Trump again urged the Supreme Court not to hear a challenge to the Medicare drug price negotiation program, arguing against a constitutional challenge brought by Boehringer Ingelheim that drug companies aren't forced to accept lower prices because they can choose not to participate. 

  • April 08, 2026

    Fed. Circ. Questions Specificity Needed In Oxy IP Invalidation

    A Federal Circuit panel expressed frustration with attorneys from both Purdue Pharma LP and generic-drug maker Accord Healthcare Inc. Wednesday as it tried to navigate whether the Delaware district court order invalidating Purdue's abuse-deterrence patent was explicit enough.

  • April 08, 2026

    Biz Judge Keeps Doc Class Action Against Luxottica, For Now

    A Texas Business Court judge Wednesday kept alive, on procedural grounds, a proposed class action made up of Texas optometrists who say that their office space deals with eye care giant Luxottica of America Inc. didn't follow Texas law.

  • April 08, 2026

    AbbVie Says 340B Program Defines 'Patient' Too Broadly

    Federally funded healthcare providers in the 340B Drug Pricing Program are using an "overly broad" interpretation of the word "patient" based on government guidelines, and it's leading to them abusing 340B discounts, AbbVie claimed in a lawsuit filed against two federal health agencies Wednesday.

  • April 08, 2026

    States Seek Time For Talks To Settle Drug Price-Fixing Suit

    The states suing generic-drug manufacturers in one of three sprawling antitrust cases want a Connecticut federal judge to pause all deadlines for three months so they can focus on settling with the remaining defendants, according to a joint filing.

  • April 08, 2026

    3M Settles Ex-Worker's COVID Vax Firing Suit

    A former 3M Co. employee who claimed the company's COVID-19 vaccination mandate policy was "unnecessary" and "draconian" has settled his more than 3-year-old suit over his firing, according to a court filing.

  • April 08, 2026

    AstraZeneca Wants 25 Opt-Ins Axed From Pay Bias Suit

    More than two dozen women refused to take part in required discovery and should be removed from a collective action accusing AstraZeneca of paying female pharmaceutical sales representatives less than men, the company told an Illinois federal court.

  • April 08, 2026

    Abbott Urges Ill. Jury To Reject Claims Formula Led To NEC

    Counsel for Abbott Laboratories told an Illinois jury Wednesday that four infants, whose mothers allege the company's preterm baby formula caused their serious intestinal illness, would have developed the disease "even without a drop of formula" given other risk factors and that the absence of other feeding options at the time of the babies' births dooms their parents' claims.

  • April 08, 2026

    Biopharma-Focused Jeito Wraps 2nd Fund With $1.2B In Tow

    Biopharmaceutical-focused private equity shop Jeito Capital on Wednesday announced that it closed its second fund above target after raising more than €1 billion ($1.2 billion) from investors.

  • April 08, 2026

    Faegre Drinker Hires 2 Venable FDA Partners In DC

    Faegre Drinker Biddle & Reath LLP has hired two attorneys from Venable LLP who joined that firm in 2023 and focus their practices on helping clients understand U.S. Food and Drug Administration regulatory frameworks, the firm announced Wednesday.

  • April 08, 2026

    Redesigned Supplement Partially Cleared In Patent Row

    A Delaware federal court has found that most of the redesigned versions of a nutritional supplement don't infringe a patent owned by Kaneka Corp., while also saying it's still unclear how much the Japanese company is owed for earlier versions the court found did infringe.

  • April 07, 2026

    Calif. Dialysis Bill Violates 1st Amendment, 9th Circ. Says

    The Ninth Circuit on Tuesday struck down provisions of a California law that aims to restrict dialysis providers' ability to profit from patients receiving health insurance premium assistance from nonprofit charities, ruling in a published opinion that the provisions violated nonprofit American Kidney Fund's and dialysis providers' First Amendment rights.

  • April 07, 2026

    Judge Says CPB Couldn't Void Harvard Researcher Visa

    A Vermont federal judge said Tuesday that a U.S. Customs and Border Protection officer at Logan Airport in Boston had no legal authority to cancel the visa of a Harvard researcher and Russian national after finding frog embryo samples in her luggage last year.

  • April 07, 2026

    NY Fertility Clinic Agrees To Settle Suit Over Destroyed Eggs

    Less than a month ahead of trial, a New York fertility clinic has agreed to resolve a suit accusing it of negligently allowing a woman's eggs to be destroyed due to alleged mishandling, according to documents filed in New York federal court.

  • April 07, 2026

    HHS Must Face States' Suit Over RFK's 'Dramatic Overhaul'

    A Rhode Island federal judge rejected Tuesday the government's bid to toss a group of states' lawsuit challenging Robert F. Kennedy Jr.'s "dramatic overhaul" of the U.S. Department of Health and Human Services, criticizing the government for rehashing jurisdictional arguments the court already rejected and finding the states' claims are plausible.

  • April 07, 2026

    Data Breach Counsel Chided For Flouting NC Court Rules

    Two attorneys looking to temporarily helm a series of putative data breach class actions targeting a radiology firm have failed to become interim co-lead class counsel, as a North Carolina Business Court judge chided them for not following rules and filing a procedurally deficient motion.

  • April 07, 2026

    Biogen, Investors Reach Deal In Alzheimer's Drug Litigation

    A class of investors has reached a deal with Biogen Inc. to avoid a trial and resolve a suit over statements executives made as they launched an Alzheimer's drug, according to a Tuesday filing in Massachusetts federal court.

  • April 07, 2026

    Minn. Can't Unfreeze $243M In Medicaid Funds, Judge Says

    A Minnesota federal judge on Monday denied the state's preliminary injunction request to release $243 million in Medicaid funds deferred by the federal government during a fraud investigation, holding that the "unprecedented" size and scope of the deferral action doesn't mean the Centers for Medicare & Medicaid Services isn't legally cleared to pursue the action.

Expert Analysis

  • Series

    Alpine Skiing Makes Me A Better Lawyer

    Author Photo

    Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.

  • FDA Guidance May Move Goalposts For Form 483 Responses

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.

  • 2 Strands Of Patent Law In High Court's 'Skinny Label' Case

    Author Photo

    Amarin v. Hikma, which is set for oral argument in the U.S. Supreme Court this month, highlights the distinction between two different strands of intellectual property law — analogizing a patent to either a property deed or a home, says Jonas McDavit at Spencer West.

  • Why MDLs Slow Down — And How To Speed Them Up

    Author Photo

    Multidistrict litigation has become central to mass tort practice, but as MDLs grow in size and complexity, so do delays and costs — so tools like the new federal rule governing MDLs, targeted use of special masters and strategically deployed Lone Pine orders are more essential than ever, say attorneys at Ice Miller.

  • A Check-Up On HHS' Push To Implement AI Infrastructure

    Author Photo

    The U.S. Department of Health and Human Services has made some headway in its efforts to implement artificial intelligence across its agencies, but will have to overcome a number of near-term tests in order to be successful, says Theodore Thompson at Stinson.

  • What A Court Doc Audit Reveals About Erroneous Filings

    Author Photo

    My audit of 1,522 court documents from last month found that over 95% contained at least one verifiable error, with fewer than 1% showing clear indicators of artificial intelligence use — highlighting above all else that lawyers may want to focus most on strengthening their review processes, says Elliott Ash at ETH Zurich.

  • Series

    Mich. Banking Brief: All The Notable Legal Updates In Q1

    Author Photo

    Michigan's financial services sector saw several significant developments in 2026's first quarter, including the state Department of Insurance and Financial Services' issuance of a bulletin on the use of artificial intelligence and the Michigan House's introduction of a bill based on the Model Money Transmission Modernization Act, say attorneys at Dykema.

  • The Road Ahead For Drug Development In The US

    Author Photo

    Against the backdrop of drug manufacturers potentially looking to move development efforts overseas, the U.S. Food and Drug Administration's latest guidance on new approach methodologies signals the FDA is likely to be receptive to industry innovation that makes U.S.-based drug development faster or less expensive, creating opportunities and compliance risks for tech companies, say attorneys at Morgan Lewis.

  • FDA's Crackdown On Drug Ads Conflicts With Precedent

    Author Photo

    Recent U.S. Food and Drug Administration warning letters to drug manufacturers targeting direct-to-consumer advertising raise significant constitutional concerns, and directly clash with prior FDA stances, say attorneys at Sidley.

  • Series

    Ultramarathons Make Me A Better Lawyer

    Author Photo

    Completing a 100-mile ultramarathon was tougher, more humbling and more rewarding than I ever imagined, and the experience highlighted how long-distance running has sharpened my ability to adapt to the evolving nature of antitrust law and strengthened my resolve to handle demanding, unforeseen challenges, says Dan Oakes at Axinn.

  • Determining When Engineered Biologics May Be Patentable

    Author Photo

    The Federal Circuit's recent decision in Regenxbio v. Sarepta, concluding that engineered cells with DNA from different organisms are not patent-ineligible natural phenomena, raises questions surrounding what framework courts will use to evaluate the patent eligibility of engineered biologics moving forward, says Robert Frederickson at Goodwin.

  • Informal Announcements Are Reshaping FDA Regulations

    Author Photo

    The U.S. Food and Drug Administration's recent shift toward using press releases, podcasts and other informal channels to announce major policy changes reflects a valid desire to modernize and accelerate regulatory efforts, but it could lead to diminished transparency, increased industry burden and reduced policy durability, says Rachel Turow at Skadden.

  • Getting The Most Out Of Learning And Development Programs

    Excerpt from Practical Guidance
    Author Photo

    Junior associates can better develop the legal, business and interpersonal skills they need for long-term success by approaching their firms’ learning and development programs armed with five tips for getting the most out of these resources, says Lauren Hakala at Reed Smith.

  • Opinion

    AI Presents A Make-Or-Break Moment For Outside Counsel

    Author Photo

    The rapid adoption of artificial intelligence by corporate legal departments is forcing a long-overdue reset of the relationship between inside and outside counsel, and introducing a significant opportunity to shed frustrating inefficiencies and strengthen collaboration for firms willing to embrace the shift, says Intel Chief Legal Officer April Miller Boise.

  • Opinion

    USPTO Has A Chance To Correct Double-Patenting Doctrine

    Author Photo

    Now that the issue of obviousness-type double patenting is front and center before the U.S. Patent and Trademark Office's Appeals Review Panel, the agency should put an end to the practice of rejecting earlier-expiring patents in favor of later-expiring ones, say attorneys at Orrick.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here